Pfizer discontinues development of capravirine

On July 1 Pfizer announced that it has discontinued clinical development of capravirine, an NNRTI with activity against NNRTI-resistant HIV, that was in phase 2 development. This came as no surprise given the complicated drug interactions that make it difficult to use with other PIs or NNRTIs.

Results reported earlier this year at the 12th Annual Conference on Retroviruses and Opportunistic Infections (CROI) indicated no benefit compared to placebo.

Source: Pfizer PR

Links to other websites are current at date of posting but not maintained.